Introduction Approved biosimilars exhibit comparable efficacy, safety, and immunogenicity to
reference products. This report provides perspectives on the societal value of biosimilars …

A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the
manufacturing process of which hinders the ability to identically replicate the structure of the …

In the history of medicine, biologicals are relatively new products. Biologicals developed in
the 1980s produced an impact in nephrology, oncology, and other therapeutic areas. The …

One of the most crucial issues in pharmacotherapy is to address the query if a patient can be
switched from one product to another of the same active substance. For the conventional …

Introduction Biosimilars are expected to improve the accessibility of biological drugs, a goal
that has not been reached because of the high cost of development. This is about to change …

With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders
including a clinician, specialist nurse, patient advocate, regulator and economist provide …

Commentary Article Ever-Evolving landscape of biosimilars in Canada; findings and implications
from a global perspective Brian G Page 1 1 Commentary Article Ever-Evolving landscape of …

As the cost of healthcare continues to rise and patents on biologics near expiration,
biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of …

Abstract The World Health Assembly resolution on access to biotherapeutics in 2014 urges
WHO and Member States to facilitate access to biotherapeutics while ensuring their quality …

The introduction of alternative versions of biologic products, also known as biosimilars, into
the United States market has been gaining increasing visibility as patents for many agents …